Thrombosis and Haemostasis, Inhaltsverzeichnis Thromb Haemost 1997; 78(01): 553-557DOI: 10.1055/s-0038-1657587 The drug trials that have influenced our clinical practice in the treatment of thrombosis Schattauer GmbH Stuttgart Drug Trials That Have Influenced Our Practice in the Treatment of Venous Thromboembolism Clive Kearon Hamilton Civic Hospitals Research Centre and McMaster University, Hamilton, Ontario, Canada › Institutsangaben Artikel empfehlen Abstract als PDF herunterladen Artikel einzeln kaufen PDF (876 kb) Referenzen References 1 Best CH. Preparation of heparin and its use in the first clinical cases. Circulation 1959; 19: 79-86 2 Wright IS. Experience with anticoagulants. Circulation 1959; 19: 110-113 3 Jorpes JE. Heparin: A mucopolysaccharide and an active antithrombotic drug. Circulation 1959; 19: 87-91 4 Mueller RL, Scheidt S. History of drugs for thrombotic disease Discovery, development, and directions for the future. Circulation 1994; 89: 432-449 5 Kakkar VV, Corrigan TP, Fossard DP. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. Lancet 1975; 02: 45-51 6 Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960; 01: 1309-1312 7 Hull R, Delmore T, Genton E. et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-858 8 Lagerstedt Cl, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; 515-518 9 Brandjes DPM, Heijboer H, Buller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with aceno-coumarol alone in the initial treatment of proximalvein thrombosis. N Engl J Med 1992; 327: 1485-1489 10 Kakkar VV, Howe CT, Flanc C, Clarke MB. Natural history of postoperative deep-vein thrombosis. Lancet 1969; 02: 230-232 11 Maynard MJ, Sculco TP, Ghelman B. Progression and regression of deep vein thrombosis after total knee arthroplasty. Clin Orthop Related Res 1991; 273: 125-130 12 Kearon C, Hirsh J. Starting prophylaxis for venous thromboembolism postoperatively. Arch Intern Med 1995; 155: 366-372 13 Sevitt S, Gallagher NG. Prevention of venous thrombosis and pulmonary embolism in injured patients. Lancet 1959; 02: 981-989 14 Gallus AS, Hirsh J, Tuttle RJ. et al. Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med 1973; 288: 545-551 15 Leyvraz PF, Richard J, Bachmann F. Adjusted versus fixed dose subcutaneous heparin in the prevention of deep vein thrombosis after total hip replacement. N Engl J Med 1983; 309: 954-958 16 Wille-Jorgensen P, Thorup J, Fischer A, Holst-Christensen J, Flamsholt R. Heparin with and without graded compression stockings in the prevention of thromboembolic complications of major abdominal surgery: a randomized trial. Br J Surg 1985; 72: 579-581 17 Tomgren S. Low dose heparin and compression stockings in the prevention of postoperative deep venous thrombosis. Br J Surg 1980; 67: 482-484 18 Ramos R, Salem BI, De Pawlikowski MP, Coordes C, Eisenberg S, Leidenfrost R. The efficacy of pneumatic compression stockings in the prevention of pulmonary embolism after cardiac surgery. Chest 1996; 109: 82-85 19 Hirsh J, Levine MN. Review: Low molecular weight heparin. Blood 1992; 79 (01) 01-17 20 Nurmohamed MT, Rosendaal FR, Buller HR. et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340: 152-156 21 Leizorovicz A, Haugh MC, Chapuis F-R, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 1992; 305: 913-920 22 Mohr DN, Silverstein MD, Murtaugh PA, Harrison JM. Prophylactic agents for venous thrombosis in elective hip surgery. Arch Intern Med 1993; 153: 2221-2228 23 Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994; 271 (22) 1780-1785 24 Anderson DR, O’Brien BJ, Levine MN, Roberts R, Wells PS, Hirsh J. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med 1993; 119: 1105-1112 25 Geerts WH, Jay RM, Code KI. et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996; 335: 701-707 26 Ginsberg JS, Nurmohamed MT, Gent M. et al. Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 1994; 90: 2385-2389 27 Eriksson BI, Ekman S, Kälebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996; 347: 635-639 28 Gardlund B. Randomised, controlled trial of low-dose heparin for prevention of fetal pulmonary embolism in patients with infectious diseases. Lancet 1996; 347: 1357-1361 29 Urokinase Pulmonary Embolism Trial. Urokinase pulmonary embolism trial: phase I results. JAMA 1970; 214: 2163-2172 30 Chiu HM, Hirsh J, Yung WL, Regoeczi E, Gent M. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 1977; 49 (02) 171-184 31 Basu D, Gallus AS, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287 (07) 324-327 32 Salzman EW, Deykin D, Mayer ShapiroR, Rosenberg R. Management of heparin therapy controlled prospective trial. N Engl J Med 1975; 292: 1046-1050 33 Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a “standard care” nomogram. Ann Intern Med 1993; 119: 874-881 34 Cruickshank MK, Levine MN, Hirsh J, Roberts RS, Siguenza M. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991; 151: 333-337 35 Gallus AS, Jackaman J, Tillett J, Mills W, Sycherley A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986; 02: 1293-1296 36 Hull RD, Raskob GE, Rosenbloom D. et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322: 1260-1264 37 Hull RD, Raskob GE, Hirsh J. et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 18 (315) 1109-1114 38 Hull R, Hirsh J, Jay R. et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307: 1676-1681 39 Hirsh J, Poller L. The international normalized ratio: A guide to understanding and correcting its problems. Arch Intern Med 1994; 154: 282-828 40 Bussey HI, Force RW, Bianco TM, Leonard AD. Reliance on prothromin time ratios causes significant errors in anticoagulation therapy. Arch Intern Med 1992; 152: 278-282 41 Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324: 1865-1875 42 O’Sullivan EF. Duration of anticoagulant therapy in venous thromboembolism. Med J Aust 1972; 02: 1104-1107 43 Holmgren KAJ, Andersson G, Fagrell B. et al. One-month versis six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis. Acta Med Scand 1985; 218: 279-284 44 Fennerty AG, Dolben J, Thomas P. et al. A comparison of 3 and 6 weeks’ anticoagulation in the treatment of venous thromboembolism. Clin Lab Haematol 1987; 09: 17-21 45 Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992; 340: 873-876 46 Levine MN, Hirsh J, Gent M. et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Hemost 1995; 74: 606-611 47 Schulman S, Rhedin A-S, Lindmarker P. et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-1665 47_a Schulman S, Granqvist S, Holmstrom M. et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336: 393-398 48 Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: meta-analysis. Br Med J 1994; 309: 299-304 49 Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. Arch Intern Med 1995; 155: 601-607 50 Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis. Am J Med 1996; 100: 269-277 51 Prandoni P, Lensing AWA, Buller HR. et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339 (8791) 441-445 52 Hull RD, Raskob GE, Pineo GF. et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-982 53 Levine M, Gent M, Hirsh J. et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-681 54 Koopman MMW, Prandoni P, Piovella F. et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334: 682-687 55 De Valk HW, Banga JD, Wester JWJ. et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann Intern Med 1995; 123: 01-09 56 Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Hemost 1993; 70: 554-561 57 Ramakrishna R, Manoharan A, Kwan YL, Kyle PW. Heparin-induced thrombocytopenia: Cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran). Br J Haematol 1995; 91: 736-738 58 Weitz JI, Califf RM, Ginsberg JS, Hirsh J, Th’roux P. New antithrombotics. Chest 1995; 108 Suppl. 471S-485S 59 McLean J. The thromboplastic action of cephalin. Am J Physiol 1976; 41: 250-257 60 Link KP. The discovery of dicoumarol and its sequels. Circulation 1959; 19: 097-107
